The University of Texas MD Anderson Cancer Center
Hematology and Oncology fellowship · Houston, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The University of Texas MD Anderson Cancer Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About The University of Texas MD Anderson Cancer Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from The University of Texas MD Anderson Cancer Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
1,376
works per year
1st of 74 hematology and oncology fellowship programs
+3.5%
2-year growth
55th of 74 hematology and oncology fellowship programs
32.5%
in top 10% of field (works before 2025)
8th of 72 hematology and oncology fellowship programs
51.6%
cited above world average
9th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 4,695Hematology · 2,071
Hematology and Oncology research topics at The University of Texas MD Anderson Cancer Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 1,236
- Acute Myeloid Leukemia Research 1,082
- CAR-T cell therapy research 553
- Pancreatic and Hepatic Oncology Research 397
- Multiple Myeloma Research and Treatments 323
- Cancer survivorship and care 312
- Hematopoietic Stem Cell Transplantation 281
- Colorectal Cancer Treatments and Studies 240
Most cited at The University of Texas MD Anderson Cancer Center since 2024
All hematology and oncology papers there on OpenAlex
- Embracing cancer complexity: Hallmarks of systemic diseaseCharles Swanton et al. · Cell · 2024 · PubMed · cited 555
- Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín et al. · Nature Medicine · 2024 · PubMed · cited 546
- The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Lisa M Force et al. · The Lancet · 2025 · PubMed · cited 498
- Ribociclib plus Endocrine Therapy in Early Breast CancerDennis J. Slamon et al. · New England Journal of Medicine · 2024 · PubMed · cited 432
- Unveiling the mechanisms and challenges of cancer drug resistanceSameer Ullah Khan et al. · Cell Communication and Signaling · 2024 · PubMed · cited 429
- [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh et al. · The Lancet · 2024 · PubMed · cited 427
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyAl B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 406
- Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trialSandra P. D’Angelo et al. · The Lancet · 2024 · PubMed · cited 319
- Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline UpdateJulienne E. Bower et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 317
- Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumoursAshley M. Holder et al. · Nature reviews. Cancer · 2024 · PubMed · cited 313